A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole

Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy male and female (non-childbearing potential) subjects aged 18 to 55 years (inclusive) at the time of signing informed consent, with suitable veins for cannulation or repeated venepuncture. * Males must be willing to use appropriate contraception methods. * Females must not be lactating and must be of non-childbearing potential. * Have a .BMI between 18.5 and 30.0 kg/m2 (inclusive) and weigh at least 50 kg and no more than 100 kg (inclusive) at Screening. Exclusion Criteria: * History of any clinically significant disease or disorder, including hyperthyroidism, uncontrolled hypothyroidism or any clinically significant thyroid disease. * History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of Investigational medicinal product (IMP). * A positive COVID-19 test at the Screening Visit or admission to the Clinical Unit. * Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis, vital signs, and 12-lead ECG. * Any positive result at the Screening Visit for serum Hepatitis B surface antigen (HBsAg), HCV, and Human immunodeficiency virus (HIV) antibody. * Known or suspected Gilbert's syndrome. * Known or suspected history of drug abuse in the last 2 years, as judged by the Investigator. * Has received another new chemical or biological entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study or final follow up visit within 1 month of first administration of IMP in this study. * Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to the Screening Visit. * History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4831 or itraconazole. * Current smokers or those who have smoked or used nicotine products (including e cigarettes). * Excessive intake of caffeine-containing drinks or foods. * Known or suspected history of alcohol or excessive intake of alcohol. * Positive screen for drugs of abuse or cotinine at screening. * Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP. * Use of any prescribed or non prescribed medication including COVID-19 vaccines, antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half life. * Subjects who have previously received AZD4831. * Subjects who are lactose intolerant or have other specific dietary restrictions that cannot be accommodated by the Clinical Unit. * Subjects who, in the opinion of the Investigator, have any clinically significant skin condition.